VANCOUVER, Sept. 17 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), announced today that it reached a favourable agreement with Johnson & Johnson's subsidiary, Conor Medsystems ("Conor") to settle all outstanding patent litigation with respect to Conor's CoStar(R) paclitaxel stent.
"With this agreement now in place, Angiotech expects that the resources required to defend and enforce our intellectual property should decrease," said Dr. William Hunter, President and CEO of Angiotech.
At the time of the settlement, there was ongoing litigation in three jurisdictions: the UK, the Netherlands and Australia.
Note on Forward Looking Statements:
Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the
words "believes," "may," "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects" and similar expressions, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and constitute "forward-looking
information" within the meaning of applicable Canadian securities laws. All
such statements are made pursuant to the "safe harbor" provisions of
applicable securities legislation. Forward-looking statements may involve,
but are not limited to, comments with respect to our objectives and
priorities for 2007 and beyond, our strategies or future actions, our
targets, expectations for our financial condition and the results of, or
outlook for, our operations, research development and product and drug
development. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved